Explore related pages
Related company profiles:
News
Tenpoint Therapeutics, Visus Therapeutics announce merger - Healio
Tenpoint Therapeutics, Visus Therapeutics announce merger Healio
Tenpoint Therapeutics and Visus Therapeutics complete merger, combining ophthalmic therapeutics portfolios - Ophthalmology Times
Tenpoint Therapeutics and Visus Therapeutics complete merger, combining ophthalmic therapeutics portfolios Ophthalmology Times
Tenpoint, Visus merge in effort to push presbyopia-correcting eye drop over FDA finish line - Fierce Biotech
Tenpoint, Visus merge in effort to push presbyopia-correcting eye drop over FDA finish line Fierce Biotech
Tenpoint Therapeutics Ltd. and Visus Therapeutics, Inc. Join Forces, Building the Next Era of Best- and First-in-Class Ophthalmic Medicines - BioSpace
Tenpoint Therapeutics Ltd. and Visus Therapeutics, Inc. Join Forces, Building the Next Era of Best- and First-in-Class Ophthalmic Medicines BioSpace
Adaptive image encryption approach using an enhanced swarm intelligence algorithm - Nature
Adaptive image encryption approach using an enhanced swarm intelligence algorithm Nature
Visus - Radiologists discover the benefits of a medical archive - healthcare-in-europe.com
Visus - Radiologists discover the benefits of a medical archive healthcare-in-europe.com
Visus Therapeutics raises $36M from J&J's VC arm, others to develop eye drop that treats presbyopia - GeekWire
Visus Therapeutics raises $36M from J&J's VC arm, others to develop eye drop that treats presbyopia GeekWire
Visus Therapeutics invites investors to $36m round - - Global Corporate Venturing
Visus Therapeutics invites investors to $36m round - Global Corporate Venturing
Enrollment complete in Visus phase 3 trial of combination drug therapy for presbyopia - Healio
Enrollment complete in Visus phase 3 trial of combination drug therapy for presbyopia Healio
Visus Therapeutics, Zhaoke Ophthalmology announce licensing agreement to commercialize presbyopia treatment overseas - Ophthalmology Times
Visus Therapeutics, Zhaoke Ophthalmology announce licensing agreement to commercialize presbyopia treatment overseas Ophthalmology Times
Visus raises $20M ahead of data drop on rival to AbbVie prospect - Fierce Biotech
Visus raises $20M ahead of data drop on rival to AbbVie prospect Fierce Biotech
Visus Therapeutics Announces New Scientific Data to Be Presented During the 2023 ARVO Annual Meeting - Business Wire
Visus Therapeutics Announces New Scientific Data to Be Presented During the 2023 ARVO Annual Meeting Business Wire
A new approach to quantify visceral fat via bioelectrical impedance analysis and ultrasound compared to MRI - Nature
A new approach to quantify visceral fat via bioelectrical impedance analysis and ultrasound compared to MRI Nature
Profile R. Visus, Widzew Łódź: Info, news, matches and statistics - besoccer.com
Profile R. Visus, Widzew Łódź: Info, news, matches and statistics besoccer.com
Visus Therapeutics presents topline clinical data from Phase 3 pivotal BRIO-I Trial of BRIMOCHOL PF for treatment of presbyopia - Ophthalmology Times
Visus Therapeutics presents topline clinical data from Phase 3 pivotal BRIO-I Trial of BRIMOCHOL PF for treatment of presbyopia Ophthalmology Times
Mykonos Visus Watch Offers A Unique Rotating Watch Face - Geeky Gadgets
Mykonos Visus Watch Offers A Unique Rotating Watch Face Geeky Gadgets
Visus Therapeutics Announces Positive Topline Clinical Data from Phase 2 VIVID Study of BRIMOCHOL for the Treatment of Presbyopia - Business Wire
Visus Therapeutics Announces Positive Topline Clinical Data from Phase 2 VIVID Study of BRIMOCHOL for the Treatment of Presbyopia Business Wire
Visus Therapeutics Expands Ophthalmic Drug Development Portfolio With Acquisition of ViewPoint Therapeutics’ Assets - Business Wire
Visus Therapeutics Expands Ophthalmic Drug Development Portfolio With Acquisition of ViewPoint Therapeutics’ Assets Business Wire
Visus Therapeutics, Inc., and Zhaoke Ophthalmology Limited Announce Exclusive Licensing Agreement to Commercialize BRIMOCHOL™ PF and Carbachol PF in Greater China, South Korea and Select Southeast Asian Markets for the Treatment of Presbyopi - Business Wire
Visus Therapeutics, Inc., and Zhaoke Ophthalmology Limited Announce Exclusive Licensing Agreement to Commercialize BRIMOCHOL™ PF and Carbachol PF in Greater China, South Korea and Select Southeast Asian Markets for the Treatment of Presbyopi Business Wire
Companies like Visus Health It Gmbh
Top Visus Health It Gmbh Employees
-
-
Alain Hucteau
Enthusiastic Digital Transformation…
Poitiers, Nouvelle-Aquitaine, France, France3neuf.fr, enovrh.fr, oracle.com2 +336769XXXXX
-
Ziad Rahhal, PMP®
Project Manager - Health Informatics |…
Germany, Germany1gmail.com -
Tim Saß
Abteilungsleiter Support Bei Visus…
Cologne Bonn Region, Germany1gmx.de
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
How It Works
Get a Free Account
Sign up for a free account. No credit card required. Up to 10 free credits.
Search the #1 Contact Database
Get contact details of over 750M+ profiles across 60M companies – all with industry-leading accuracy. Sales Navigator and Recruiter users, try out our Email Finder Extension.
Use our AI-Powered Email Finder
Find business and personal emails and mobile phone numbers with exclusive coverage across niche job titles, industries, and more for unparalleled targeting. Also available via our Contact Data API.